Medicus Pharma Marks Nasdaq Anniversary with Opening Bell Ceremony

Opening Bell ceremony marks growth and clinical momentum for biotech innovator

Medicus Pharma marked its first anniversary as a Nasdaq-traded company with an Opening Bell ceremony in Times Square, spotlighting pipeline progress and strategic direction.

Medicus Pharma Ltd. (NASDAQ: MDCX) marked the completion of its first year on the Nasdaq exchange by hosting an Opening Bell ceremony at the Nasdaq MarketSite in New York’s Times Square.

The milestone reflects the company’s focus on advancing selected clinical programs through proof-of-concept Phase 2 studies while pursuing licensing and partnership opportunities with seasoned industry players.

Major assets in the company’s pipeline include SkinJect, a precision immunogenic therapy for the most common form of skin cancer, and Teverelix, a novel hormone antagonist for complex prostate cancer cases. Together, these programs address large unmet medical needs with billions in estimated market potential.

The Nasdaq anniversary event underscores Medicus’ strategic execution since going public and positions the company for continued clinical momentum and investor engagement.

For more information on Medicus Pharma (NASDAQ: MDCX) please click on the request investor info button.

‍